Literature DB >> 24021889

The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris: a noncontrolled study.

Ayse Serap Karadag1, Derun Taner Ertugrul, Goknur Kalkan, Serap Gunes Bilgili, Huseyin Tugrul Celik, Zennure Takci, Ragıp Balahoroglu, Omer Calka.   

Abstract

BACKGROUND/AIM: To investigate the effects of acitretin treatment on insulin resistance (IR) and adipokines, particularly retinol-binding protein (RBP)-4.
METHODS: Thirty-four patients with chronic plaque psoriasis and a control group of 34 healthy volunteers were recruited in the study. Screening for the parameters was performed before starting and after 3 months of acitretin treatment in the psoriasis group. The control group was only evaluated at the beginning of the study and did not receive placebo. We could not compare our results with a placebo control group because of ethical reasons.
RESULTS: Basal adiponectin (p = 0.01), insulin (p < 0.0001) levels and homeostasis model assessment (HOMA) IR (p < 0.0001) were significantly higher in psoriasis patients. After the treatment, insulin (p = 0.014), C peptide (p = 0.011), RBP-4 (p < 0.0001) levels and HOMA-IR (p = 0.008) decreased significantly. Posttreatment leptin (p = 0.036) levels were significantly lower than those of the controls. Posttreatment adiponectin (p = 0.005) and insulin (p = 0.048) levels were higher than those of the controls.
CONCLUSIONS: This study showed for the first time that RBP-4 levels and IR are decreased significantly with acitretin treatment. This finding is very important in psoriasis patients because psoriasis may cause insulin resistance and diabetes. Further experimental and clinical studies are needed to clarify the effect of acitretin on adipocyte structure and behavior.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24021889     DOI: 10.1159/000351769

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  8 in total

Review 1.  Peroxisome proliferator-activator receptor γ and psoriasis, molecular and cellular biochemistry.

Authors:  Xiran Lin; Xianmin Meng; Zhiqi Song; Jingrong Lin
Journal:  Mol Cell Biochem       Date:  2022-03-29       Impact factor: 3.396

Review 2.  Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time.

Authors:  Eva Klara Merzel Šabović; Mateja Starbek Zorko; Miodrag Janić
Journal:  Int J Mol Sci       Date:  2022-06-14       Impact factor: 6.208

3.  Retinoid Chemoprevention: Who Can Benefit?

Authors:  Rodica P Bunaciu; Andrew Yen
Journal:  Curr Pharmacol Rep       Date:  2015-04-15

Review 4.  Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies.

Authors:  Deepak M W Balak; Stefano Piaserico; Ismail Kasujee
Journal:  Psoriasis (Auckl)       Date:  2021-12-07

5.  Association of Adipokines, Insulin Resistance, Hypertension and Dyslipidemia in Patients with Psoriasis Vulgaris.

Authors:  Melis Coban; Levent Tasli; Sebahat Turgut; Seyma Özkan; Melek Tunç Ata; Fulya Akın
Journal:  Ann Dermatol       Date:  2016-01-28       Impact factor: 1.444

Review 6.  New insights into different adipokines in linking the pathophysiology of obesity and psoriasis.

Authors:  Yi Kong; Suhan Zhang; Ruifang Wu; Xin Su; Daoquan Peng; Ming Zhao; Yuwen Su
Journal:  Lipids Health Dis       Date:  2019-09-14       Impact factor: 4.315

7.  Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1).

Authors:  J L W Lambert; S Segaert; P D Ghislain; T Hillary; A Nikkels; F Willaert; J Lambert; R Speeckaert
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-08       Impact factor: 6.166

Review 8.  Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions.

Authors:  Yan Hao; Ya-Juan Zhu; Song Zou; Pei Zhou; Ya-Wen Hu; Qi-Xiang Zhao; Lin-Na Gu; Hao-Zhou Zhang; Zhen Wang; Jiong Li
Journal:  Front Immunol       Date:  2021-07-23       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.